Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
REPAY Stock Rises After Visa Platform Connect Collaboration 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Add as a preferred source on Google
SAN DIEGO, May 03, 2018 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Thursday, May 10, 2018 at 5:00 p.m. ET to report its first quarter 2018 financial results and provide a corporate update.
In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 5592629. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Fate Therapeutics is headquartered in San Diego, CA.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]
